DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report)'s stock price fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $2.41 and last traded at $2.42. 5,238 shares traded hands during trading, a decline of 87% from the average session volume of 41,772 shares. The stock had previously closed at $2.51.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Oppenheimer reissued an "outperform" rating and set a $6.00 price objective (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum cut their price target on DiaMedica Therapeutics from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 21st.

DiaMedica Therapeutics Trading Down 3.6 %

The company's 50-day simple moving average is $2.81 and its 200-day simple moving average is $2.70. The stock has a market capitalization of $91.86 million, a price-to-earnings ratio of -3.90 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). On average, equities research analysts expect that DiaMedica Therapeutics Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonebridge Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics during the 3rd quarter worth about $52,000. Paragon Associates & Paragon Associates II Joint Venture lifted its stake in shares of DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company's stock valued at $1,420,000 after purchasing an additional 30,000 shares during the period. Finally, Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.